Microneedling uses a device with tiny, sterile needles to create thousands of shallow perforations in the skin. This low risk, quickly healing procedure creates a controlled wound response in the skin that stimulates collagen production and skin rejuvenation that then continues on for months.
A TGA-approved microneedling pen is loaded with a new sterile TGA-approved needle cartridge. The depth of the needle penetration is selected on the pen depending on the reason for treatment and location being treated. The aim is to create a wound, but to minimise pin point bleeding. The device is typically passed over each area 6 to 8 times, creating a flushed response. We use a topical broad-spectrum antimicrobial spray to facilitate gliding of our needle cartridges. This water based solution is non-toxic, non-irritating and also promotes wound healing.
The skin is cleaned of all products and sterilised. Depending on the area to be treated and the depth of the needle penetration, a topical anaesthetic cream may need to be applied to the area. That cream is covered with plastic film and left for about an hour. The cream is then removed and the area is carefully cleaned and sterilised.
There may be some pinpoint bleeding during the process. This is dependent on the area treated and the reason for treating. Once the pinpoint bleeding is washed off, the face is left somewhat flushed. On occasion there is minor bruising the following day. The treated area may peel in the week after treatment.
No products should be applied to the treated area until the following day. A rich moisturiser should be used. Active topicals should be avoided until the skin has recovered - typically 2 to 5 days. We recommend Healite II treatment 2 days before, immediately after and 2 to 4 days after microneedling. We have found it an excellent treatment that both reduces healing time and increases the effectiveness of microneedling. This treatment will also minimise bruising and flushing.
Bleeding disorders. Active acne, or other infections in the area being treated. Patients with strong keloidal tendency. Herpes or warts in the area being treated.